IOVA · NASDAQ
Iovance Biotherapeutics (IOVA) Stock Price & Fundamentals
Iovance Biotherapeutics (IOVA) closed at $287.46 on Oct 9, 2026, up 0.63% from the previous close of $285.66.
Share price, past year
1Y +15.92%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $287.46 |
| Sep 30, 2026 | $281.60 |
| Aug 31, 2026 | $279.02 |
| Jul 31, 2026 | $264.88 |
| Jun 30, 2026 | $253.89 |
| May 29, 2026 | $237.24 |
| Apr 30, 2026 | $233.03 |
| Mar 31, 2026 | $218.88 |
| Feb 27, 2026 | $237.26 |
| Jan 30, 2026 | $235.48 |
| Dec 31, 2025 | $238.45 |
| Nov 28, 2025 | $236.57 |
| Oct 31, 2025 | $241.92 |
Key statistics
- Market cap
- $130.21B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $324.97M
- Net income (TTM)
- −$289.52M
- Shares outstanding
- 453M
- Dividend yield
- —
- 52-week range
- $216.14 – $288.96
Iovance Biotherapeutics's market cap is $130.21B, based on a share price of $287.46 and 453M shares outstanding as of Jun 30, 2026.
Financials
Iovance Biotherapeutics reported revenue of $263.50M for fiscal 2025, up 60.60% from fiscal 2024.
Iovance Biotherapeutics reported a net loss of $390.98M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $263.50M | +60.6% | −$390.98M | −148.4% | −$1.09 | −$336.24M |
| FY2024ended Dec 31, 2024 | $164.07M | +13,699.0% | −$372.18M | −226.8% | −$1.28 | −$364.05M |
| FY2023ended Dec 31, 2023 | $1.19M | — | −$444.04M | −37,345.4% | −$1.89 | −$384.11M |
| FY2018ended Dec 31, 2018 | $0.00 | — | −$123.58M | — | −$1.27 | −$102.45M |
| FY2017ended Dec 31, 2017 | $0.00 | — | −$92.06M | — | −$1.41 | −$79.74M |
| FY2016ended Dec 31, 2016 | $0.00 | — | −$52.89M | — | −$1.85 | −$34.19M |
| FY2015ended Dec 31, 2015 | $0.00 | — | — | — | — | — |
| FY2014ended Dec 31, 2014 | $0.00 | — | — | — | — | — |
| FY2013ended Dec 31, 2013 | $0.00 | — | — | — | — | — |
| FY2012ended Dec 31, 2012 | $0.00 | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $99.31M | −$47.32M | −$0.11 |
| Q1 FY2026ended Mar 31, 2026 | $71.43M | −$79.05M | −$0.19 |
| Q4 FY2025ended Dec 31, 2025 | $86.77M | −$71.90M | — |
| Q3 FY2025ended Sep 30, 2025 | $67.46M | −$91.25M | — |
| Q2 FY2025ended Jun 30, 2025 | $59.95M | −$111.66M | −$0.33 |
| Q1 FY2025ended Mar 31, 2025 | $49.32M | −$116.16M | −$0.36 |
| Q4 FY2024ended Dec 31, 2024 | $73.69M | −$78.56M | −$0.24 |
| Q3 FY2024ended Sep 30, 2024 | $58.56M | −$83.54M | −$0.28 |
Company profile
- Name
- Iovance Biotherapeutics, Inc.
- Ticker
- IOVA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 825 Industrial Road, 4th Floor, San Carlos, CA 94070
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001425205
Recent SEC filings
- Oct 5, 2026
- Sep 29, 2026
- Aug 6, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jul 2, 2026
- Jun 10, 2026
- May 7, 2026
Frequently asked questions
What is Iovance Biotherapeutics's stock price?
Iovance Biotherapeutics (IOVA) closed at $287.46 on Oct 9, 2026, up 0.63% from the previous close of $285.66.
What is Iovance Biotherapeutics's market cap?
Iovance Biotherapeutics's market cap is $130.21B, based on a share price of $287.46 and 453M shares outstanding as of Jun 30, 2026.
How much revenue does Iovance Biotherapeutics make?
Iovance Biotherapeutics reported revenue of $263.50M for fiscal 2025, up 60.60% from fiscal 2024.
Does Iovance Biotherapeutics pay a dividend?
Iovance Biotherapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Iovance Biotherapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures